ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...
Amsterdam, the Netherlands – Nov. 1, 2023 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes - MuSK+, LRP4+, triple ...
Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.
BREDA, Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune ...
BREDA, the Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback